Wells Fargo & Company Monopar Therapeutics Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.59 - $0.94 $568 - $905	963 Added 62.65%	2,500 $1,000
Q1 2024 May 10, 2024	BUY	$0.31 - $1.35 $465 - $2,025	1,500 Added 4054.05%	1,537 $1,000
Q4 2023 Feb 09, 2024	BUY	$0.29 - $0.6 $1 - $2	4 Added 12.12%	37 $0
Q2 2023 Aug 15, 2023	BUY	$0.84 - $1.43 $1 - $2	2 Added 6.45%	33 $0
Q4 2022 Feb 13, 2023	BUY	$2.05 - $14.95 $2 - $14	1 Added 3.33%	31 $0
Q3 2022 Nov 14, 2022	BUY	$1.46 - $7.6 $1 - $7	1 Added 3.45%	30 $0
Q2 2022 Aug 12, 2022	BUY	$1.85 - $2.72 $5 - $8	3 Added 11.54%	29 $0
Q3 2021 Nov 15, 2021	SELL	$4.5 - $6.0 $4 - $6	-1 Reduced 3.7%	26 $0
Q2 2021 Aug 16, 2021	BUY	$5.05 - $6.49 $40 - $51	8 Added 42.11%	27 $0
Q4 2020 Feb 09, 2021	BUY	$4.36 - $7.49 $21 - $37	5 Added 35.71%	19 $0
Q3 2020 Nov 05, 2020	BUY	$4.93 - $8.15 $69 - $114	14 New	14 $0

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $316M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.